Chapman B J, Farquahar D L, Galloway S M, Simpson G K, Munro J F
Eastern General Hospital, Edinburgh, U.K.
Int J Obes. 1988;12(2):119-23.
Beta-adrenoceptor agonists have recently been shown to promote substantial loss of adipose tissue in laboratory animals. One of these BRL, 26830A, increases thermogenesis in human volunteers and has been shown to enhance the rate of weight reduction in patients adhering to a strict reducing regimen. Forty-three post-menopausal or sterilized female subjects suffering from refractory obesity participated in a double-blind placebo-controlled study, the treatment group receiving BRL 26830A 50 mg qid. Two subjects were withdrawn because they developed an unpleasant sensation of tremor and in all, 17 of the 20 who received BRL 26830A mentioned this side effect. There was no change in erect or supine blood pressure or in resting heart rate. There was no significant difference in weight change during the 6-week study. It is concluded that BRL 26830A does not appear to promote weight reduction in subjects unable to adhere strictly to their dietary regime.
β -肾上腺素能受体激动剂最近已被证明可促使实验动物的脂肪组织大量减少。其中一种药物BRL 26830A可增加人类志愿者的产热，并已证明可提高严格遵循减肥方案的患者的体重减轻速度。43名患有顽固性肥胖的绝经后或绝育女性受试者参与了一项双盲安慰剂对照研究，治疗组接受BRL 26830A，50毫克，每日四次。两名受试者因出现不愉快的震颤感觉而退出，在所有接受BRL 26830A治疗的20名受试者中，共有17人提到了这种副作用。直立或仰卧血压以及静息心率均无变化。在为期6周的研究中，体重变化无显著差异。结论是，对于无法严格遵循饮食方案的受试者，BRL 26830A似乎不会促进体重减轻。
